• Company’s i/Blue Imaging System(TM) is expected to be completed in 2022
• The American Cancer Society estimates that 2021 will see 83,370 new cases of bladder cancer and approximately 17,200 deaths
• More than half of the patients who underwent a cystoscopy to remove non-muscle-invasive bladder cancer will experience recurrence 
• The bladder cancer market was valued at $3.43 billion in 2020, and is anticipated to reach $4.71 billion by 2028

According to the American Cancer Society, new cases of bladder cancer in the United States are expected to reach 83,730 in 2021 and deaths are anticipated to reach 17,200 (https://ibn.fm/zNRWl). Approximately 50% of patients who have had minimally invasive surgery to remove non-muscle-invasive bladder cancer will see their cancer return (https://ibn.fm/cdSKN). Scientists’ current areas of focus include the identification and causes/predictors of recurrence, as bladder cancer remains not only one of the most prevalent forms of cancer, but also one with a very high recurrence rate. 

To potentially help lower this high recurrence rate, surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF) is finalizing the design-for-manufacturing of the i/Blue Imaging System, an innovative technology designed to significantly improve surgeons’ ability to visualize cancerous cells and enable more accurate bladder cancer resection. The company’s patented technology will display blue and white light images of the bladder side-by-side simultaneously, providing surgeons better visualization to remove cancer.

White light cystoscopy is still the industry standard in over 90% of the procedures performed. The largest drawback with white light is that only the cancerous tumors that protrude from the bladder wall are easily identified. Using only white light, it is almost impossible to differentiate flat tumors from regular tissue and create clean margins, which means cancerous cells might be left behind and cause recurrence. 

Blue light cystoscopy (“BLC”) addresses this challenge by using a contrast agent that fluoresces the cancerous cells, both those along the margins and flat tumors, a vast improvement over white light cystoscopy. By enhancing visualization for the surgeon, BLC has been proven to detect 25% more cancerous tumors. 

However, resection cannot be completed using blue light images alone. Surgeons use the blue light image to see the cancer but need the white light image to determine the position within the bladder, requiring them to switch back and forth between the white light and blue light images and rely on memory to resect. 

Imagin Medical’s i/Blue Imaging System will help overcome this and other challenges. The company’s advanced technology will show both images simultaneously side-by-side on one screen, providing surgeons with better visualization to remove the cancer and making procedures more efficient.

Imagin Medical’s technology is currently in the manufacturing stage with Lighthouse Imaging, an FDA-registered and ISO 13485:2016 certified manufacturer. The i/Blue Imaging System is expected to be completed in 2022. The technology fits most existing endoscopes on the market, allowing medical facilities to continue using scopes they already have without costly equipment investments. This feature allows hospitals and physicians to provide their patients with the latest technology at a lower cost, making potential widespread adoption easier.

Leveraging this innovative technology, Imagin Medical is uniquely positioned to disrupt the bladder cancer market. The global bladder cancer therapeutics market was valued at $3.43 billion in 2020 and is expected to grow at a CAGR of 4.03% from 2021 to 2028, to reach $4.71 billion by 2028. Factors affecting this are the escalation of bladder cancer, increased awareness of available therapies, growing healthcare expenditure, and more (https://ibn.fm/p0jei). 

Although Imagin Medical is currently focused on bladder cancer, the company intends to expand its technology to other types of minimally invasive surgery in the future, such as laparoscopic, and accommodate multiple fluorescing imaging agents such as hexaminolevulinate (“HLA”) and Indocyanine green (“ICG”).

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.